Bio-View Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 1/6
Bio-View's earnings have been declining at an average annual rate of -14.2%, while the Medical Equipment industry saw earnings growing at 8.4% annually. Revenues have been growing at an average rate of 1.6% per year. Bio-View's return on equity is 3%, and it has net margins of 2.6%.
Anahtar bilgiler
-14.2%
Kazanç büyüme oranı
-13.4%
EPS büyüme oranı
| Medical Equipment Sektör Büyümesi | 15.2% |
| Gelir büyüme oranı | 1.6% |
| Özkaynak getirisi | 3.0% |
| Net Marj | 2.6% |
| Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Shareholders Will Probably Not Have Any Issues With Bio-View Ltd's (TLV:BIOV) CEO Compensation
Dec 04
Estimating The Intrinsic Value Of Bio-View Ltd (TLV:BIOV)
Feb 14Does BioView Ltd.'s (TLV:BIOV) Weak Fundamentals Mean That The Market Could Correct Its Share Price?
Jan 20What BioView Ltd.'s (TLV:BIOV) 35% Share Price Gain Is Not Telling You
Nov 29
Gelir ve Gider Dağılımı
Bio-View nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 34 | 1 | 13 | 9 |
| 31 Mar 24 | 35 | 1 | 13 | 9 |
| 31 Dec 23 | 35 | 0 | 13 | 8 |
| 30 Sep 23 | 34 | 0 | 13 | 7 |
| 30 Jun 23 | 34 | 2 | 12 | 6 |
| 31 Mar 23 | 31 | 1 | 12 | 5 |
| 31 Dec 22 | 29 | 1 | 12 | 5 |
| 30 Sep 22 | 29 | 1 | 11 | 5 |
| 30 Jun 22 | 30 | 1 | 11 | 6 |
| 31 Mar 22 | 30 | 2 | 10 | 5 |
| 31 Dec 21 | 31 | 2 | 10 | 5 |
| 30 Sep 21 | 30 | 2 | 9 | 5 |
| 30 Jun 21 | 28 | 2 | 9 | 5 |
| 31 Mar 21 | 28 | 2 | 8 | 5 |
| 31 Dec 20 | 26 | 1 | 9 | 5 |
| 30 Sep 20 | 29 | 2 | 9 | 5 |
| 30 Jun 20 | 31 | 2 | 10 | 5 |
| 31 Mar 20 | 35 | 3 | 10 | 6 |
| 31 Dec 19 | 36 | 3 | 10 | 6 |
| 30 Sep 19 | 34 | 2 | 10 | 6 |
| 30 Jun 19 | 29 | -1 | 11 | 6 |
| 31 Mar 19 | 27 | -1 | 11 | 6 |
| 31 Dec 18 | 25 | -2 | 11 | 7 |
| 30 Sep 18 | 25 | -2 | 10 | 7 |
| 30 Jun 18 | 28 | 0 | 10 | 8 |
| 31 Mar 18 | 27 | -2 | 10 | 7 |
| 31 Dec 17 | 28 | -1 | 10 | 7 |
| 30 Sep 17 | 29 | 1 | 10 | 6 |
| 30 Jun 17 | 29 | 1 | 10 | 6 |
| 31 Mar 17 | 32 | 3 | 10 | 6 |
| 31 Dec 16 | 33 | 4 | 11 | 6 |
| 30 Sep 16 | 34 | 4 | 11 | 6 |
| 30 Jun 16 | 32 | 3 | 11 | 6 |
| 31 Mar 16 | 33 | 3 | 12 | 5 |
| 31 Dec 15 | 35 | 4 | 12 | 6 |
| 30 Sep 15 | 32 | 3 | 12 | 5 |
| 30 Jun 15 | 33 | 3 | 13 | 5 |
| 31 Mar 15 | 32 | 3 | 12 | 5 |
| 31 Dec 14 | 30 | 2 | 12 | 5 |
| 30 Sep 14 | 28 | 1 | 12 | 6 |
| 30 Jun 14 | 27 | 1 | 11 | 5 |
| 31 Mar 14 | 24 | 0 | 11 | 5 |
| 31 Dec 13 | 23 | -1 | 10 | 6 |
Kaliteli Kazançlar: BIOV has a large one-off gain of ₪493.0K impacting its last 12 months of financial results to 30th June, 2024.
Büyüyen Kar Marjı: BIOV's current net profit margins (2.6%) are lower than last year (6.2%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: BIOV has become profitable over the past 5 years, growing earnings by -14.2% per year.
Büyüme Hızlandırma: BIOV's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Kazançlar vs. Sektör: BIOV had negative earnings growth (-57.8%) over the past year, making it difficult to compare to the Medical Equipment industry average (-2.4%).
Özkaynak Getirisi
Yüksek ROE: BIOV's Return on Equity (3%) is considered low.